Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

Enrolling by invitation

Conditions studied: Parkinson Disease

In brief

This is a multicenter study to evaluate the safety and clinical outcomes of BRT-DA01 in subjects with PD who previously received BRT-DA01 in the Phase 1 Study MSK-DA01-101.No investigational therapy will be administered in this study.

Key facts

Study ID

NCT05897957

Run by

BlueRock Therapeutics

People needed

12

Starts

2023-05-16

Expected to finish

2027-09-01

Last updated by the study team

2024-04-12

Who can join

Age: 50 and older, up to 78. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subject received BRT-DA01 in Study MSK-DA01-101 (ie, parent study) and will have completed or discontinued the parent study
• Subject must be willing and able to provide written informed consent for the BRT-DA0-501 study in accordance with applicable regulations and guidelines and to comply with all study visits and procedures

You may not qualify if…

• No exclusion criteria

Where it is running

• University of California, Irvine — Orange, California, United States
• Weill Cornell Medical College — New York, New York, United States
• Toronto Western Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.